Obesity pharmacotherapy often is solely equated as therapeutic use of anti-obesity medications (AOMs). In this session, two important factors in obesity pharmacotherapy will be discussed. This will include discussing weight promoting medications (WPM) and secondly discussing indication for use pharmacotherapy by the FDA. Weight promoting medications (WPM) are associated with increased adiposity and development of obesity related conditions in all populations. This session will define and categorize WPM, discuss the potential consequences of their use, and discuss best practices in prescribing weight neutral medications or mitigating the effects of WPM if alternatives are unavailable. This session also clarifies how and why medications are classified as “on-label” or “off-label” for indication by the FDA. Case studies will demonstrate management of WPM and knowledge of FDA indication into the comprehensive weight management plan. This presentation is aimed at the pediatric population but is pertinent across the lifespan. Guidance available in the OMA pediatric clinical practice statements will be highlighted.

CME/CE Expiration Date: 10/21/23

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.